The clinical use of full-length mAbs as imaging agents can be challenging, due to their long biological half-life and relatively slow tumor penetration, which may affect tumor-to-background contrast at early time points. To circumvent these issues, Dr Gabriela Kramer-Marek’s team has developed radiolabeled affibody-based PET tracers that still have high specificity and affinity of the potential therapeutic mAb, but their molecular weight below 60 kDa allows for rapid renal clearance and elimination.
In this webinar, Dr Gabriela Kramer-Marek will focus on HER-specific imaging radioconjugates that could provide unique information as cancer biomarkers, including quantification of receptor heterogeneity and early detection of changes in target expression in response to therapy.
Dr Kramer-Marek will introduce the immuno-PET techniques the Preclinical Molecular Imaging Team are using at The Institute of Cancer Research in London, with a focus on imaging HER3 receptor, which is increasingly being recognized as a key player in therapeutic resistance in HER2 and EGFR-driven cancers. She will discuss affibody-based PET agents as potential new imaging biomarkers for personalized assessment of drug resistance and early prediction of patient treatment responses.
The main topics that will be covered include:
The webinar would appeal to basic biologists, radiochemists, clinicians and drug developers interested in the use of immuno-PET in clinical trials. Researchers in the field of cancer biology and immunotherapy who are interested in immune checkpoint inhibitors would also benefit.
Dr Gabriela Kramer-Marek
Dr Ali Asgar Attarwala